tradipitant

Sponsor Vanda Pharmaceuticals INC. · listed as VNDA

READOUT Phase 3 Confidence: medium Source: clinicaltrials

tradipitant is a clinical-stage drug asset sponsored by Vanda Pharmaceuticals INC., listed as VNDA. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Dec 1, 2026 (day precision, medium confidence), tied to trial NCT07446439. The asset is in Phase 3 and currently recruiting, studied in Nausea and Vomiting.

Next catalyst

Event typeREADOUT

Expected date2026-12-01

As disclosedDec 1, 2026

Date precisionday

Confidencemedium

Verify at source →

Trial & sponsor

Trial (NCT)NCT07446439

PhasePHASE3

StatusRECRUITING

Lead sponsorVanda Pharmaceuticals

Listed asVNDA

Condition(s)Nausea and Vomiting; Obesity

Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.

This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.

Get the full dataset — $499 → More VNDA catalysts